Immunome posts updated investor presentation suggesting combination with Morphimmune; no deal terms disclosed

Immunome Inc.

On July 5, 2023, Immunome filed Form 8-K announcing posting of an updated investor presentation on its website.
Presentation is titled 'Morphimmune and Immunome Combined Corporate Presentation,' indicating a potential transaction.
No financial details, merger agreement, or definitive terms are provided in the filing or available exhibit text.
Filing does not include any forward-looking guidance, revenue impact, or timeline for the proposed combination.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.